BGPT: Paper Review: ULK1 promotes mitophagy via phosphorylation and stabilization of BNIP3

Explore by Goal

Quick Explanation Copied

Core claim (mechanism): ULK1 directly phosphorylates BNIP3 at S17 (and BNIP3L at S35) to promote LC3 binding and mitophagy, and also stabilizes BNIP3 by limiting proteasome-dependent turnover in a way that depends on BNIP3’s BH3 domain.

Two mechanistic “levers” supported by experiments:

Phosphorylation lever: ULK1 inhibition (ULK-101) blocks phosphorylation in vitro and reduces LC3 interaction/mitophagy when BNIP3 S17 cannot be phosphorylated.
Stability lever: ULK1 kinase activity limits proteasome-dependent turnover of BNIP3/BNIP3L under hypoxia, partially rescued by MG132.

Long Explanation

Paper Review

ULK1 promotes mitophagy via phosphorylation and stabilization of BNIP3

DOI: 10.1038/s41598-021-00170-4 • Scientific Reports (2021)

What the paper tries to solve

How ULK1 mechanistically promotes mitophagy when BNIP3/BNIP3L are mitochondrial cargo receptors.

Mechanistic hypothesis as a testable network (visual)

The authors propose a dual-lever mechanism: ULK1 (1) phosphorylates BNIP3 S17 to enhance LC3 binding and (2) stabilizes BNIP3 by limiting proteasomal turnover in a BH3-dependent manner.

Quantitative anchors the paper states (from reported fold-changes)

Bar chart shows the reported in vitro phosphorylation reductions (ULK1→32P) when the relevant serines are mutated.

Phosphomimetic enhances LC3 interaction more strongly under flux-blocking conditions

The text reports that bafilomycin A1 increases LC3B pull-down with BNIP3 S17E by 9.0-fold, vs 2.5-fold for WT, consistent with increased mitophagic flux (though note: pull-down ≠ complete flux definition).

Expected phenotype directionality from the S17 mutants

The paper’s narrative consistently orders: S17E > WT > S17A (for LC3 interaction, mitophagy, reduced mitochondria/respiration; also stronger growth slowdown with S17E).

1) Main findings—what is strongly supported vs interpretive

A. ULK1 is the kinase for BNIP3 S17 (and BNIP3L S35)

In vitro phosphorylation: recombinant ULK1 robustly phosphorylates recombinant BNIP3 and BNIP3L; phosphorylation is inhibited by the ULK1 inhibitor ULK-101; S→A mutations at the claimed sites reduce phosphorylation.
Site plausibility: the authors align BNIP3 S17 / BNIP3L S35 context with an ULK1 substrate consensus derived from prior substrate mapping work.

Skeptical note: In vitro kinase assays strongly support direct phosphorylation by ULK1, but cellular causality still depends on whether (i) ULK1 is the dominant kinase in those cellular contexts and (ii) additional sites/modifications (e.g., S24/S34) are regulated by other kinases. The paper itself suggests S24/S34 are likely not ULK1-dependent.

B. Phosphorylation status maps onto LC3 interaction and mitophagy-like readouts

LC3 binding: BNIP3 S17A reduces interaction with GFP-LC3B compared with WT (approaching the effect of disrupting the LIR residue W18).
Phosphomimetic: BNIP3 S17E phosphomimetic increases LC3 binding and enhances mitophagy-associated phenotypes (mitochondrial removal signals, lysosomal co-staining with TOMM20).

Important methodological skepticism: “Mitophagy flux” claims are interpreted using combination of bafilomycin A1 effects and imaging/interaction readouts. While bafilomycin is commonly used to block lysosomal acidification and thereby accumulate autophagic structures, pulldowns of LC3 and overlap quantification are not identical to complete flux measurements such as mito-QC-style reporters. The paper uses multiple strategies, but any flux conclusion should be weighted by which assays directly measure turnover vs recruitment.

C. ULK1 increases BNIP3/BNIP3L protein stability via proteasome protection

ULK1 inhibition lowers BNIP3/BNIP3L under hypoxia; MG132 partially rescues, while bafilomycin A1 does not rescue the decrease in BNIP3 levels, arguing for a proteasome-linked stability mechanism rather than simply lysosome-mediated turnover.
Turnover kinetics: they use a cycloheximide chase after DFO withdrawal to show ULK1 inhibition accelerates BNIP3 decay, and MG132 co-treatment protects against this decay.

D. BH3 domain dependency: stability modulation is not simply phosphosite-driven

BH3 deletion stabilizes BNIP3 even without ULK1, and ULK1’s ability to further increase levels is lost (or greatly reduced) for the BH3-deleted mutant, indicating BH3 domain is key for the degradation control.
Phosphorylation still matters for LC3 interaction: even when BH3 is deleted (which increases LC3 interaction via higher protein levels), S17 mutation status dominates interaction with LC3, suggesting phosphorylation is the “interaction switch” while BH3 influences stability and thus effective cargo availability.

2) Strengths

Direct enzymology + cellular phenotypes: the study connects recombinant kinase assays (direct phosphorylation) to cellular interaction, imaging, metabolic readouts (Seahorse OCR), and growth.
Mechanistic separation: the paper attempts to disentangle LC3 interaction from stability by using BH3 deletions and phosphosite mutants, and reports differential effects (S17 affects LC3 binding dominance; BH3 deletion affects stability).
Pharmacological inhibitor triangulation: ULK-101 and TBK1 inhibitor (MRT67307) show both ULK1 and potentially TBK1 impacts BNIP3/BNIP3L abundance, and they monitor pathway activity readouts (pS555 ULK1, pS29 ATG14, pTBK1 S172).

3) Limitations, blind spots, and falsification points

A. Overexpression dependence & cancer-cell context

A large portion of mechanistic readouts uses transient or stable overexpression (FLAG-ULK1; HA-BNIP3 mutants; GFP-LC3B pull-down). Overexpression can inflate interactions and may not reflect endogenous occupancy. The paper does include endogenous BNIP3/BNIP3L hypoxia induction and proteasome turnover experiments, which partially offsets this concern.

B. “Mitophagy flux” vs recruitment

The authors interpret bafilomycin-dependent increases in LC3 binding as evidence for increased mitophagic flux. This is reasonable but not equivalent to measuring complete mitochondrial clearance across time with turnover reporters (e.g., mito-QC-style). Thus, falsifying outcomes would include observations that S17E increases LC3 recruitment without increasing actual mitochondrial removal or that bafilomycin effects reflect altered degradation kinetics unrelated to cargo flux.

C. Mechanism of BH3-dependent proteasomal turnover remains unresolved

The study strongly shows BH3 deletion stabilizes BNIP3 and is critical for ULK1’s stability regulation, but it does not identify the E3 ligase(s) nor the exact ubiquitination topology controlling BNIP3 degradation. The paper notes future work is needed to identify ligases.

D. Additional kinase input: TBK1 may confound stability narratives

The TBK1 inhibitor decreases BNIP3/BNIP3L levels without synchronously decreasing ULK1 activity readouts (pS29 ATG14), suggesting TBK1 could regulate BNIP3 stability via independent routes. Thus, the ULK1→BNIP3 stability story may represent one major axis rather than a sole control mechanism.

E. In vivo generality not established in this specific paper

This mechanistic paper focuses on human cancer cell lines and biochemical assays. The question “does ULK1 phosphorylate BNIP3 at S17 in vivo to regulate mitophagy under physiological hypoxia?” remains open without direct in vivo phosphosite evidence. That is a key falsification target.

Pathway context: where ULK1 fits relative to known mitophagy/autophagy regulation

ULK1 is the core catalytic component of the autophagy initiation complex (ULK1 complex) and regulates downstream autophagy via phosphorylation of initiation machinery components.

4) What you can do with this paper (testable checklist)

Claim type	Key evidence in paper	Falsification target
Direct phosphorylation	Recombinant ULK1 phosphorylates BNIP3 S17 / BNIP3L S35; ULK-101 inhibits; S→A reduces signal.	Demonstrate in vivo that S17 phosphorylation does not track ULK1 activity or is catalyzed by another kinase under physiological hypoxia.
LC3 interaction switch	S17A reduces LC3B binding; S17E boosts LC3 association and mitophagy-associated mitochondrial/lysosomal phenotypes.	Show that S17E increases recruitment but not turnover (e.g., using mitochondrial clearance reporters) or that LC3 interaction is mediated by indirect effects not phosphorylation-specific.
Stabilization mechanism	ULK-101 decreases BNIP3/BNIP3L levels in hypoxia; MG132 partially rescues; CHX chase shows ULK1 inhibition accelerates BNIP3 decay.	Identify BNIP3 ubiquitination topology and E3 ligase(s) mediating turnover; if BH3 deletion stabilizes without affecting ULK1 dependence in physiological systems, the model needs revision.

Author reviews (jump to perspectives)

Feedback:

Updated: April 05, 2026